Search results
Results from the WOW.Com Content Network
Chordoma is a rare slow-growing neoplasm thought to arise from cellular remnants of the notochord.The evidence for this is the location of the tumors (along the neuraxis), the similar immunohistochemical staining patterns, and the demonstration that notochordal cells are preferentially left behind in the clivus and sacrococcygeal regions when the remainder of the notochord regresses during ...
Chondrosarcoma is a bone sarcoma, a primary cancer composed of cells derived from transformed cells that produce cartilage. [1] A chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas .
M9221/3 Juxtacortical chondrosarcoma Periosteal chondrosarcoma; M9230/0 Chondroblastoma, NOS Chondromatous giant cell tumor; Codman tumor; M9230/3 Chondroblastoma, malignant M9231/3 Myxoid chondrosarcoma M9240/3 Mesenchymal chondrosarcoma M9241/0 Chondromyxoid fibroma M9242/3 Clear cell chondrosarcoma M9243/3 Dedifferentiated chondrosarcoma
Europe and other parts of the world use the ICD-10. The root codes for ICD-10 and ICD-10-CM are the same, making it helpful for locating codes for general body systems and disease processes. [2] [3] In ICD-11 the search and coding of any disease, including rare ones is done via the ICD-11 website. [4]
ASPS arises mainly in children and young adults and can migrate (metastasize) into other parts of the body, typically the lungs and the brain. Typically, ASPS arises in muscles and deep soft tissue of the thigh or the leg (lower extremities), but can also appear in the upper extremities (hands, neck, and head). While ASPS is a soft tissue ...
Download QR code; Print/export Download as PDF; Printable version; ... Myxoid chondrosarcoma is a type of chondrosarcoma. [1] It has been associated with a t(9;22) ...
The stage of the sarcoma is based on the size and grade of the tumor, and whether the cancer has spread to the lymph nodes or other parts of the body (metastasized). Treatment options for soft-tissue sarcomas include surgery, radiotherapy, chemotherapy, and targeted drug therapy. [3]
EMC was firstly described in 1953 by Stout et al. when they discussed the different species of extraskeletal chondrosarcoma, [2] but EMC concept was firstly proposed in 1972 by Enzinger et al. [3] Brody thought that this was a unique low-grade malignancy with a low growth rate and both clinically and histopathologically distinct anamnesis beside the typical chondrosarcomas. [4]